These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1841042)

  • 21. [In vitro comparative effect of cefixime and 7 other beta-lactamines against Streptococcus pneumoniae].
    Boussougant Y; Weber P
    Presse Med; 1989 Oct; 18(32):1553-5. PubMed ID: 2530530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in vitro activity of the new oral cephalosporin cefixime.
    Counts GW; Baugher LK; Ulness BK; Hamilton DJ
    Eur J Clin Microbiol Infect Dis; 1988 Jun; 7(3):428-31. PubMed ID: 3137053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro antibacterial activity of cefixime.
    Lin SR; Peng CF
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1988 Oct; 4(10):586-91. PubMed ID: 3230604
    [No Abstract]   [Full Text] [Related]  

  • 24. Revised disk diffusion interpretive criteria for cefaclor, loracarbef, cefprozil and cefixime when testing Haemophilus influenzae on haemophilus test medium.
    Doern GV; Jones RN; Gerlach EH; Hindler J; St Amand R
    Eur J Clin Microbiol Infect Dis; 1994 Jun; 13(6):481-9. PubMed ID: 7957268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.
    Nies BA
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):558-61. PubMed ID: 2504600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines.
    Gerlach EH; Jones RN; Allen SD; Koontz FP; Murray PR; Pfaller MA; Washington JA; Erwin ME
    Diagn Microbiol Infect Dis; 1992 Aug; 15(6):537-43. PubMed ID: 1424507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cefixime shows good effects on group A and group B beta-haemolytic streptococci.
    Liberto MC; Carbone M; Fera MT; Berlinghieri MC; Puccio R; Focà A; De Luca M; Casini A
    Drugs Exp Clin Res; 1991; 17(6):305-8. PubMed ID: 1769318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overview of the clinical features of cefixime.
    Adam D
    Chemotherapy; 1998 Sep; 44 Suppl 1():1-5. PubMed ID: 9797415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.
    Kamimura T; Kojo H; Matsumoto Y; Mine Y; Goto S; Kuwahara S
    Antimicrob Agents Chemother; 1984 Jan; 25(1):98-104. PubMed ID: 6561017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins].
    Bauernfeind A; Jungwirth R; Schweighart S; Theopold M
    Infection; 1990; 18 Suppl 3():S155-67. PubMed ID: 2079378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacteriological comparison of cefixime in patients with noncomplicated urinary tract infection in Spain. Preliminary results.
    García-Rodríguez JA
    Chemotherapy; 1998 Sep; 44 Suppl 1():28-30. PubMed ID: 9797421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
    Schatz BS; Karavokiros KT; Taeubel MA; Itokazu GS
    Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in vitro activity of norfloxacin and seven other antimicrobial agents against clinical isolates from urinary tract infections.
    Esko E; Renkonen OV
    Scand J Infect Dis; 1985; 17(1):95-8. PubMed ID: 3158071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effectiveness and tolerance of cefixime in bacterial urinary tract infections in patients with myelomeningocele].
    Carstens C; Hostalek U
    Klin Padiatr; 1994; 206(1):22-5. PubMed ID: 8152202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates.
    Murray PR; Allen SD; Erwin ME; Gerlach EH; Jones RN; Koontz FP; Pfaller MA; Washington JA
    Eur J Clin Microbiol Infect Dis; 1991 Sep; 10(9):776-81. PubMed ID: 1810737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects of cefixime and cefaclor on pharyngeal flora in children].
    Sakata H; Maruyama S
    Kansenshogaku Zasshi; 1991 May; 65(5):546-51. PubMed ID: 1880444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Alteration of bacteria induced by subinhibitory concentrations of cefixime: consequences on bactericidal activity of human polynuclear neutrophils].
    Labro MT; el Benna J; Jemni A
    Pathol Biol (Paris); 1992 May; 40(5):427-32. PubMed ID: 1495824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cefixime in urinary tract infections. (Specific studies and literature review)].
    Naber KG
    Infection; 1990; 18 Suppl 3():S132-9. PubMed ID: 2079373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of loracarbef and effects of susceptibility test methods.
    Doern G
    Am J Med; 1992 Jun; 92(6A):7S-15S. PubMed ID: 1621748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of cefixime (FK 027) for resistant gram-negative bacilli.
    Smith SM; Eng RH
    Chemotherapy; 1988; 34(6):455-61. PubMed ID: 3243091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.